SESN News and Press, Sesen Bio Inc.

Sesen Bio ( NASDAQ: SESN ) stockholders on Thursday approved effecting a 1-for-20 reverse stock split of the company's issued and outstanding shares. The information was disclosed in a regulatory filing . The reverse stock split will be effective as of March 7. The reverse...

Clinical-stage biotech Sesen Bio ( NASDAQ: SESN ) announced Thursday that its shareholders greenlighted the company’s pending merger with Carisma Therapeutics at a special meeting of stockholders held today. Based on early voting results, more than 88% of votes were in favor of...

Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...

Sesen Bio press release ( NASDAQ: SESN ): Q4 GAAP EPS of -$0.04 beats by $0.07 . Cash, cash equivalents and marketable securities were $166.9 million as of December 31, 2022, compared to cash and cash equivalents of $162.6 million as of December 31, 2021. Sesen Bio Board...

Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...

Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...

Report Highlights Compelling Strategic Rationale, Estimated Potential Value to Shareholders of $0.88 per Share and Downside Risk of Non-Approval Positive Recommendation Supports Boards’ Belief That Carisma Merger Maximizes Value for Stockholders Reiterates Support from Seve...

Sesen Bio, Inc. (Nasdaq: SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. (“Carisma”) management team on Tuesday, February 21, 2023, at 8:00 am ET. The discussion will cover Sesen Bio’s pending m...

Sesen Bio Board Unanimously Recommends All Stockholders to Vote “FOR” the Value Maximizing Merger on the WHITE Proxy Card Today Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that BML Investment Partners, L.P. (&#...

Sesen Bio ( NASDAQ: SESN ) added ~11% pre-market Tuesday in reaction to an agreement with two key shareholders to obtain support for its pending merger with privately held Carisma Therapeutics under amended terms. The shareholders, Bradley Radoff and Michael Torok, who own approxi...